Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

2017 ◽  
Vol 120 (3) ◽  
pp. 394-400 ◽  
Author(s):  
Peter K. Chiu ◽  
Arnout R. Alberts ◽  
Lionne D. F. Venderbos ◽  
Chris H. Bangma ◽  
Monique J. Roobol
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Additional Benefit ◽  
Selection For ◽  
Biopsy Complications

scholarly journals The use of European Randomized study of Screening for Prostate Cancer calculator as a diagnostic tool for prostate biopsy indication

2019 ◽  
Vol 120 (05) ◽  
pp. 331-335
Author(s):  
J. Breza ◽  
F. Subin ◽  
M. Bernadic ◽  
M. Tomas ◽  
D. Pindak
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Diagnostic Tool ◽  
Randomized Study

scholarly journals A review of optimal prostate biopsy: indications and techniques

2019 ◽  
Vol 11 ◽  
pp. 175628721987007 ◽  
Author(s):  
Justin Streicher ◽  
Brian Lee Meyerson ◽  
Vidhya Karivedu ◽  
Abhinav Sidana
Keyword(s):  
Prostate Cancer ◽  
Patient Selection ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Diagnostic Technique ◽  
Fusion Biopsy ◽  
Advantages And Disadvantages ◽  
Software Platforms ◽  
Selection For

Prostate biopsy is the gold standard diagnostic technique for the detection of prostate cancer. Patient selection for prostate biopsy is complex and is influenced by emerging use of prebiopsy imaging. The introduction of the magnetic resonance imaging (MRI)–transrectal ultrasound (TRUS) fusion prostate biopsy has clear advantages over the historical standard of care. There are several biopsy techniques currently utilized with unique advantages and disadvantages. We review and summarize the current body of literature pertaining to when and how a prostate biopsy should be performed. We discuss current recommendations regarding patient selection for biopsy and discuss future directions regarding prebiopsy imaging. We offer a description of the MRI–TRUS fusion biopsy technique and a comparison of many of the currently available fusion software platforms. Articles pertaining to the title were obtained via PubMed index search with relevant keywords supplemented with personal collection of related publications. Prostate biopsy should be considered for patients with gross digital rectal exam (DRE) abnormality, patients with a prostate-specific antigen (PSA) greater than 4 ng/ml, and concomitant risk factors for prostate cancer or patients with lesions identified on multiparametric MRI (mpMRI) with Prostate Imaging Reporting and Data System 2 (PI-RADS2) score of 4 or 5. MRI–TRUS fusion biopsy has demonstrated advantages in cancer detection when compared with TRUS-guided biopsy. There are currently several fusion software platforms available with a variety of biopsy approaches. Future efforts should detail the role of prebiopsy imaging as a triage tool for prostate biopsy. Consensus should be sought regarding the preferred modality of fusion biopsy. Additional data describing each fusion software platform would enable a more rigorous comparison of platform sensitivities.

The Incidence of Prostate Cancer in Men With Prostate Specific Antigen Greater Than 4.0 Ng/Ml:: A Randomized Study Of 6 Versus 12 Core Transperineal Prostate Biopsy

2004 ◽  
Vol 171 (1) ◽  
pp. 197-199 ◽  
Author(s):  
PAOLO EMILIOZZI ◽  
PAOLO SCARPONE ◽  
FRANCESCO DePAULA ◽  
MAURIZIO PIZZO ◽  
GIORGIO FEDERICO ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Specific Antigen ◽  
Transperineal Prostate Biopsy
Sign in / Sign up

Export Citation Format

Share Document